BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 22, 2004
 |  BioCentury  |  Tools & Techniques

Making fragments stable

Among the many companies developing third-generation antibodies, ESBATech AG is focusing on single chain antibodies, especially single chain variable fragments. But while scFVs have advantages such as increased tissue penetration, ease of engineering and the potential to add other effectors, they also have limitations such as poor stability and solubility, a short half life in vivo and a high tendency to aggregate, thereby...

Read the full 299 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >